6RK73 / Mission Therap - LARVOL DELTA

Potential Anti-Cancer Drug 6RK73 Suppresses Ovarian Cancer Growth by Inactivating the AKT1/Sp1 Induced c-Myc Signaling Pathway. (PubMed, J Cancer) - "Finally, AKT1 overexpression reversed the 6RK73-mediated suppression of cell proliferation by reactivating the AKT1/Sp1/c-Myc signaling pathway. These findings suggest that 6RK73 is a promising anti-cancer agent that exerts its effects by inactivating AKT1/Sp1/c-Myc signaling in ovarian cancer."

Journal • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Targeted Protein Degradation • AKT1 • UCHL1

Deubiquitinase UCHL1 stabilizes KDM4B to augment VEGF signaling and confer bevacizumab resistance in clear cell renal cell carcinoma. (PubMed, Transl Oncol) - "Overall, this study defined an epigenetic mechanism of UCHL1/KDM4B in activating VEGF signaling. The UCHL1-KDM4B axis represents a novel target for treating ccRCC and improving the efficacy of anti-angiogenesis therapy."

Journal • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • EPAS1 • KDM4B • UCHL1